Requires health insurance coverage for amino acid-based elemental formulas (EN INCREASE GF EX See Note)
Summary
HB 467 requires health insurance issuers in Louisiana that cover maternity services to provide coverage for amino acid-based elemental formulas for infants and children age two or younger when the formula is medically necessary. The bill applies to children diagnosed by a board-certified allergist or gastroenterologist and supported by a written order from the treating physician. Covered conditions include multiple food protein allergies, severe food protein-induced enterocolitis syndrome, eosinophilic disorders confirmed by biopsy, and impaired nutrient absorption caused by gastrointestinal disorders. Coverage must be provided regardless of delivery method.
The bill also extends the same coverage requirement to Medicaid through the Louisiana Department of Health, and to managed care entities contracting with the state to serve Medicaid recipients. It allows coverage to be subject to normal plan cost-sharing, such as deductibles, copayments, and coinsurance, and permits utilization review of the physician’s medical-necessity determination. The act is named the “Darcy Evelyn Bivins Act” and applies to new policies and renewals after the effective date, but only after a separate appropriation is enacted to fund implementation.
Impact
HB 467 amends Louisiana insurance law by creating new mandated-benefit provisions in Title 22 and a parallel Medicaid coverage requirement in Title 40. It affects health insurers, health coverage plans, HMOs, managed care organizations, and the Louisiana Department of Health by requiring them to cover amino acid-based elemental formulas under specified clinical criteria. The bill also establishes implementation timing tied to future appropriations and policy renewal cycles, which delays full effect until funding is provided and plans can conform.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House and Senate unanimously at each recorded vote, including final passage and subsequent actions on amendments and conference report. The voting history suggests the measure was viewed favorably as a targeted health coverage mandate for medically vulnerable infants and children.
Contention
There is little evidence of substantive controversy in the available record. The main policy questions embedded in the bill are whether insurers and Medicaid should be required to cover these specialized formulas, how broadly medical necessity should be reviewed, and whether normal cost-sharing should apply. The bill also conditions effectiveness on a specific appropriation, which may reflect concern about fiscal impact and implementation costs, but no recorded debate or dissent is available in the provided materials.